Global Primary Aldosteronism Market Growth (Status and Outlook) 2023-2029

Global Primary Aldosteronism Market Growth (Status and Outlook) 2023-2029

Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches.

LPI (LP Information)' newest research report, the “Primary Aldosteronism Industry Forecast” looks at past sales and reviews total world Primary Aldosteronism sales in 2022, providing a comprehensive analysis by region and market sector of projected Primary Aldosteronism sales for 2023 through 2029. With Primary Aldosteronism sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Aldosteronism industry.

This Insight Report provides a comprehensive analysis of the global Primary Aldosteronism landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Aldosteronism portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Aldosteronism market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Aldosteronism and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Aldosteronism.

The global Primary Aldosteronism market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Aldosteronism market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Blood Test
Imaging Test

Segmentation by application
Hospitals
Specialty Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Sun Pharmaceutical Industries
Bristol Laboratories
CMP Pharma
Koninklijke Philips
GE Healthcare
Siemens
Shimadzu Corporation
Canon

Please note: The report will take approximately 2 business days to prepare and deliver.